4otk
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | == | + | ==A structural characterization of the isoniazid Mycobacterium tuberculosis drug target, Rv2971, in its unliganded form== |
<StructureSection load='4otk' size='340' side='right' caption='[[4otk]], [[Resolution|resolution]] 1.60Å' scene=''> | <StructureSection load='4otk' size='340' side='right' caption='[[4otk]], [[Resolution|resolution]] 1.60Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[4otk]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OTK OCA]. <br> | + | <table><tr><td colspan='2'>[[4otk]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OTK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OTK FirstGlance]. <br> |
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MLI:MALONATE+ION'>MLI</scene><br> | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MLI:MALONATE+ION'>MLI</scene><br> | ||
| - | <tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span></td></tr> | ||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4otk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4otk OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4otk RCSB], [http://www.ebi.ac.uk/pdbsum/4otk PDBsum]</span></td></tr> | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4otk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4otk OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4otk RCSB], [http://www.ebi.ac.uk/pdbsum/4otk PDBsum]</span></td></tr> | ||
<table> | <table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Aldo-keto reductases (AKR) are a large superfamily of NADPH-dependent oxidoreductases and play a role in detoxification of toxic metabolites. Rv2971, an AKR in Mycobacterium tuberculosis, has recently been identified as a target of isoniazid, a key first-line drug against tuberculosis. Here, the cloning, expression, purification, crystallization and structural characterization of Rv2971 are described. To gain insight into its function, the crystal structure of Rv2971 was successfully determined to 1.60 A resolution in its unliganded form. The structure exhibits a TIM-barrel fold typical of AKRs, revealing structural characteristics essential for function and substrate specificities, allowing a structural comparison between Rv2971 and other mycobacterial AKRs. | ||
| + | |||
| + | A structural characterization of the isoniazid Mycobacterium tuberculosis drug target, Rv2971, in its unliganded form.,Shahine A, Prasetyoputri A, Rossjohn J, Beddoe T Acta Crystallogr F Struct Biol Commun. 2014 May;70(Pt 5):572-7. doi:, 10.1107/S2053230X14007158. Epub 2014 Apr 17. PMID:24817712<ref>PMID:24817712</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Revision as of 04:44, 4 June 2014
A structural characterization of the isoniazid Mycobacterium tuberculosis drug target, Rv2971, in its unliganded form
| |||||||||||
